

Table of Contents

VOLUME 1

About the Editors	v
About the Contributors	vii
Table of Chapters	xxxv
Introduction to Second Edition	lxxiii

PART I TRENDS IN PRODUCT CLAIMS AND DEFENSES

Chapter 1 What Product Liability Might Look Like in the Twenty-First Century

James M. Beck

§ 1:1	Introduction	1-1
§ 1:2	What Is a Product?	1-2
§ 1:3	Who Is a Manufacturer/Supplier?	1-7
§ 1:4	What Is a Defect?	1-10
§ 1:5	What Should Be the Standard of Liability?.....	1-11
§ 1:6	Causation, Genetics and Genomics.....	1-14
§ 1:7	Injury	1-15
§ 1:8	Procedural Issues	1-16

Chapter 2 Recent Trends in Product Claims and Product Defenses

Lori B. Leskin & Angela R. Vicari

§ 2:1	Overview	2-2
§ 2:2	Multidistrict Litigation	2-3
§ 2:2.1	Increased Diversity in MDLs	2-3
§ 2:2.2	Consolidation	2-5

PRODUCT LIABILITY LITIGATION

§ 2:3 Class Actions..... 2-6

 § 2:3.1 Economic Injury Class Actions 2-7

 § 2:3.2 Waiver of Class Actions 2-7

§ 2:4 Personal Jurisdiction..... 2-7

 § 2:4.1 Impact on Cases Filed in Federal Court 2-9

 § 2:4.2 Impact on Nationwide Class Actions..... 2-9

 § 2:4.3 Other Questions on the Scope of Personal
 Jurisdiction 2-10

§ 2:5 Third-Party Financers 2-10

§ 2:6 Preemption 2-13

 § 2:6.1 Brand-Name Drugs: Failure-to-Warn 2-13

 § 2:6.2 Brand Name Manufacturer Liability for
 Generic Drugs..... 2-16

 § 2:6.3 Medical Devices..... 2-18

 [A] Application of Preemption to Hybrid
 Medical Devices..... 2-19

 [B] FDA Pilot Program..... 2-19

 [C] Admissibility of 510(k) Evidence..... 2-20

 § 2:6.4 Food..... 2-21

§ 2:7 Electronic Discovery 2-22

 § 2:7.1 Rule 37(e)..... 2-22

 § 2:7.2 Ethics in e-Discovery 2-23

§ 2:8 Emerging Technology..... 2-23

 § 2:8.1 Three-Dimensional (3D) Printing..... 2-23

 § 2:8.2 Contact Tracing 2-25

 § 2:8.3 The Internet of Things 2-26

 § 2:8.4 Autonomous Technology..... 2-27

 [A] Autonomous Vehicles 2-27

 [A][1] State Legislation and Preemption 2-27

 [A][2] Causes of Actions Available to Plaintiffs 2-28

 [A][3] Evidentiary Issues 2-28

 [A][4] Defenses Available to Manufacturers 2-29

 [B] Autonomous Robotic Surgery..... 2-30

§ 2:9 Conclusion 2-31

**Chapter 3 Game-Changers: Defending Products Cases
with Child Plaintiffs**

Sandra Giannone Ezell & Diana M. Miller

§ 3:1 Overview 3-2

§ 3:2 Legal Strategies for Avoiding the “Blame Game”..... 3-2

 § 3:2.1 Generally 3-2

 § 3:2.2 Contributory, Comparative, and Imputed
 Negligence 3-3

Table of Contents

§ 3:2.3	Product Misuse and Alteration	3-5
§ 3:2.4	Parents As “Learned Intermediaries”	3-9
[A]	Learned Intermediary Doctrine.....	3-9
[B]	Last Clear Chance Doctrine.....	3-10
§ 3:2.5	State-of-the-Art/Industry Standard Defense	3-11
§ 3:3	Discovery.....	3-12
§ 3:3.1	Generally	3-12
§ 3:3.2	Get to Know the Parents and Siblings	3-12
§ 3:3.3	Deposing Children.....	3-13
§ 3:4	Sympathy at Trial: Acknowledge It	3-15
§ 3:4.1	Generally	3-15
§ 3:4.2	Voir Dire.....	3-15
§ 3:4.3	Trial Techniques for Cross-Examining Grieving Parents and the Injured Child	3-16
§ 3:4.4	Damages: Removing Sympathy from the Equation	3-16
[A]	Generally	3-16
[B]	Annuity Evidence.....	3-17
[C]	Mathematical Evidence.....	3-18
§ 3:5	Conclusion	3-19

Chapter 4 Preemption Defenses

*Joseph G. Petrosinelli, Paul E. Boehm &
Amy Mason Saharia*

§ 4:1	Overview	4-2
§ 4:2	Initial Considerations in Responding to Litigation	4-3
§ 4:2.1	Removal from State Court to Federal Court.....	4-3
§ 4:2.2	Failure to State a Claim	4-4
§ 4:3	Standard of Review; Presumptions; Rules of Interpretation; and Agency Deference.....	4-4
§ 4:3.1	Standard of Review	4-4
§ 4:3.2	Presumptions and Rules of Interpretation.....	4-5
§ 4:3.3	Agency Deference	4-6
§ 4:4	Types of Preemption	4-7
§ 4:4.1	Express Preemption and Savings Clauses.....	4-7
§ 4:4.2	Implied Preemption	4-9
§ 4:4.3	Impossibility Preemption.....	4-9
§ 4:4.4	Obstacle Preemption.....	4-10
§ 4:4.5	Field Preemption.....	4-10
§ 4:4.6	Administrative Preemption.....	4-11
§ 4:5	Preemption Involving Pharmaceutical Failure-to-Warn Claims	4-12

§ 4:6	“Innovator Liability” in Pharmaceutical Failure-to-Warn Cases.....	4-17
§ 4:7	Preemption Involving Medical Devices.....	4-18
§ 4:8	Preemption in Aviation.....	4-21
§ 4:9	Preemption Involving Vessels	4-23
§ 4:10	Preemption Involving Motor Vehicles.....	4-24
§ 4:11	Preemption Involving Trains.....	4-27
§ 4:12	Preemption in Other Areas: Cigarettes and Pesticides.....	4-28
§ 4:12.1	Cigarettes.....	4-28
§ 4:12.2	Pesticides	4-29
§ 4:13	Conclusion	4-29

Chapter 5 Defending Class Action Lawsuits

Mark Herrmann, Pearson N. Bownas & Katherine Garceau Sobiech

§ 5:1	Overview	5-2
§ 5:2	Class Action Basics.....	5-5
§ 5:2.1	Generally	5-5
§ 5:2.2	“Threshold” Requirements for Class Certification.....	5-6
[A]	Ascertainable Class.....	5-6
[B]	Representative’s Membership in the Proposed Class.....	5-10
[C]	Claim That Is Not Moot	5-11
§ 5:2.3	Rule 23(a).....	5-13
[A]	Generally	5-13
[B]	Numerosity.....	5-14
[C]	Commonality	5-14
[D]	Typicality	5-14
[E]	Adequacy	5-15
§ 5:2.4	Rule 23(b)	5-16
§ 5:2.5	A Subclass Must Individually Satisfy Rule 23	5-19
§ 5:2.6	<i>Shady Grove Orthopedic Associates v. Allstate Insurance Co.</i> and the Relationship Between Rule 23 and State Rules Regarding Class Certification.....	5-20
§ 5:3	Federal Subject Matter Jurisdiction Over Product Liability Class Actions.....	5-22
§ 5:3.1	Generally	5-22
§ 5:3.2	Class Action Fairness Act’s Jurisdictional, Removal, and Appeal Provisions	5-23
[A]	Expanded Diversity Jurisdiction.....	5-23

Table of Contents

[B]	Exceptions	5-24
[C]	Liberalized Removal and Appeal Provisions	5-25
§ 5:3.3	Other Sources of Diversity Jurisdiction Over Class Actions	5-26
§ 5:3.4	<i>Bristol-Myers Squibb</i> and Personal Jurisdiction	5-26
§ 5:4	Moving to Dismiss the Named Plaintiff’s Individual Claims	5-29
§ 5:5	Moving to Dismiss the Class Allegations	5-30
§ 5:6	Precertification Discovery	5-31
§ 5:6.1	Generally	5-31
§ 5:6.2	Differences Between Named Plaintiff’s and Class Members’ Claims	5-32
§ 5:6.3	Bifurcation of Discovery.....	5-33
§ 5:6.4	Scheduling	5-34
§ 5:7	Communicating with Class Members	5-34
§ 5:8	Moving for Summary Judgment on the Named Plaintiff’s Claims	5-35
§ 5:9	Prevailing on the Class Certification Decision.....	5-36
§ 5:9.1	Generally	5-36
§ 5:9.2	“Triability” Arguments Against Class Certification.....	5-37
[A]	Generally	5-37
[B]	Individual Issues Secondary to Predominating Class Issues	5-40
[C]	Rule 23(c)(4)(A) Issue Certification	5-41
[D]	Choice-of-Law Issues	5-42
[E]	<i>Eisen v. Carlisle & Jacquelin</i>	5-44
§ 5:9.3	Due Process Arguments Against Class Certification.....	5-46
§ 5:9.4	Other Arguments Against Certification	5-49
[A]	Immaturity	5-49
[B]	Improper Expert Testimony Supporting Certification	5-49
§ 5:10	Pretrial Post-Certification Relief: Decertification and Appeal.....	5-52
§ 5:10.1	Generally	5-52
§ 5:10.2	Decertification	5-52
§ 5:10.3	Appeal.....	5-53
§ 5:11	Notice and Opt-Out	5-55
§ 5:12	Trying a Product Liability Class Action.....	5-57

Chapter 6 Litigation in Foreign Countries Against U.S. Companies

Joseph G. Petrosinelli & Benjamin W. Graham

§ 6:1	Overview	6-1
§ 6:2	Initial Considerations in Responding to Foreign Litigation	6-2
§ 6:2.1	Retaining Foreign Counsel	6-2
§ 6:2.2	International Privilege Considerations	6-3
§ 6:2.3	Venue Challenges	6-4
§ 6:2.4	Pretrial Asset Seizures	6-5
§ 6:2.5	Obtaining Foreign Evidence	6-5
§ 6:3	U.S. Implications of Foreign Litigation	6-7
§ 6:3.1	Parallel U.S. Litigation	6-7
§ 6:3.2	Settlement of U.S. Litigation	6-10
§ 6:3.3	U.S. Governmental Inquiries/Actions	6-11
§ 6:3.4	Enforceability of Adverse Foreign Judgments	6-13
§ 6:3.5	Implications of Foreign Criminal Cases	6-17
§ 6:4	Conclusion	6-18

Chapter 7 Emerging Issues in Pharmaceutical Litigation

Allen P. Waxman, Loren H. Brown & Brooke Kim

§ 7:1	Overview	7-2
§ 7:2	Individual Claims and Coordinated Actions	7-3
§ 7:2.1	Locating the Mass Action: Jurisdictional Disputes	7-3
[A]	The Rise of the MDL	7-3
[B]	Preservice Removal	7-5
[C]	Post-BMS State Court Litigation	7-7
§ 7:2.2	The Eroding Learned Intermediary Doctrine?	7-11
§ 7:2.3	Innovator Liability: Liability Without Product Identification	7-13
§ 7:2.4	Litigation Funding	7-16
§ 7:2.5	Mass Torts in the Social Media Era	7-18
§ 7:3	Promotion Inconsistent with or Beyond Product Labels	7-19
§ 7:3.1	Generally	7-20
§ 7:3.2	Safe Harbor Provisions of State Consumer Fraud Statutes	7-20
§ 7:3.3	Class Certification in Consumer Fraud Class Actions	7-22
§ 7:4	Government Investigations and Litigation	7-24
§ 7:4.1	The Anti-Kickback Statute and False Claims Act	7-25

Table of Contents

§ 7:4.2 Enforcement Related to Opioid Products..... 7-27

§ 7:4.3 Enforcement Related to Patient Assistance
Programs and Donations to Copay Charities 7-29

§ 7:4.4 Enforcement Related to Rising Drug Cost..... 7-31

§ 7:4.5 DOJ Policy Shift..... 7-32

§ 7:5 Trends in Securities Claims Against Healthcare
Companies 7-33

§ 7:5.1 Government Regulation of Securities Issued by
Pharmaceutical and Biotechnology Companies..... 7-34

§ 7:5.2 Healthcare Companies Are Increasingly Facing
Private Securities Litigation Claims 7-35

§ 7:5.3 The Pharmaceutical and Biotechnology
Industry Is Susceptible to Private Litigation
Due to an Ambiguous Disclosure Standard 7-36

§ 7:6 Conclusion 7-40

**Chapter 8 Recent Developments in Asbestos, Talc, Silica,
Tobacco, and E-Cigarette/Vaping Litigation in
the U.S. and Canada**

*George Gigounas, Arthur Hoffmann, David Jaroslaw,
Amy Pressman, Nancy Shane Rappaport, Wendy
Michael, Christopher Gismondi, Stephen H. Barrett,
Micah Chavin, Adam A. DeSipio, Ryan McNamara,
Sean Newland, Becky Rock, Greg Sperla &
Michael Lisanti*

§ 8:1 Asbestos Litigation: United States 8-3

§ 8:1.1 The “Bare-Metal Defense” and Whether a
Manufacturer Can Be Liable for Injuries
Caused by Products It Did Not Make, Sell,
or Distribute 8-3

§ 8:1.2 Personal Jurisdiction 8-5

[A] Motions to Dismiss 8-6

[B] Consent by Registration..... 8-7

[C] Cases Spread Across More Jurisdictions..... 8-9

[D] Fewer Defendants Listed and/or Remaining
after Motion to Dismiss..... 8-9

§ 8:1.3 Causation Rulings..... 8-9

[A] Every Exposure/Breath Causes Injury..... 8-9

[B] DNA..... 8-13

§ 8:1.4 Workers’ Compensation Statutes Are Changing..... 8-14

§ 8:1.5 Federal Officer Removal 8-15

[A] Satisfying the Elements of 28 U.S.C. § 1442 8-19

[B] Logistics of Removal 8-22

PRODUCT LIABILITY LITIGATION

§ 8:2	Asbestos Litigation: Canada	8-22
§ 8:2.1	Overview.....	8-22
§ 8:2.2	Federal Regulation.....	8-23
§ 8:2.3	Partial Ban of Asbestos.....	8-24
§ 8:2.4	Provincial Regulation	8-25
§ 8:2.5	Canadian Asbestos-Related Litigation.....	8-27
	[A] Product Liability Lawsuits.....	8-27
	[B] Class Action Lawsuits.....	8-29
	[C] Why Are Product Liability Claims Less Numerous in Canada?.....	8-30
§ 8:2.6	Future Developments in Canadian Asbestos Litigation	8-31
§ 8:3	Talc Litigation: United States	8-32
§ 8:3.1	Asbestos Contamination Cases	8-32
	[A] Background.....	8-32
	[A][1] Industrial and Cosmetic Talc Cases	8-32
	[A][2] Asbestos Not an Intended Ingredient	8-32
	[B] Verdict Trends.....	8-33
§ 8:3.2	Ovarian Cancer Caused by Talc	8-33
	[A] Background.....	8-33
	[B] Verdicts.....	8-34
	[C] Scientific Evidence	8-35
	[D] MDL and MCL.....	8-37
§ 8:4	Talc Litigation: Canada.....	8-37
§ 8:4.1	Introduction.....	8-37
	[A] Legislative Context	8-37
	[B] New Developments	8-39
	[C] Litigation History	8-39
	[C][1] Administrative Tribunals.....	8-39
	[C][2] The <i>Kramar</i> Class Action.....	8-40
	[C][3] Pending Litigation	8-41
§ 8:4.2	Differences from the United States.....	8-42
	[A] Legislative Context	8-42
	[B] Litigation Context	8-43
§ 8:4.3	Anticipated Developments in Canada.....	8-43
§ 8:5	Silica Litigation: United States and Canada.....	8-43
§ 8:5.1	Overview.....	8-43
§ 8:5.2	History of Litigation.....	8-44
	[A] U.S. Litigation	8-44
	[B] Canadian Litigation.....	8-45
	[C] Future Developments in Canada	8-46
§ 8:6	Traditional Tobacco Litigation: United States	8-46
§ 8:6.1	The “Engle Progeny” Actions.....	8-46
§ 8:6.2	Two Engle Progeny Cases Are Before the Florida Supreme Court.....	8-47

Table of Contents

§ 8:6.3	Federal Appellate Activity and Engle Progeny Actions	8-48
§ 8:6.4	Traditional Tobacco Litigation Continues	8-49
§ 8:6.5	Synergy Theory	8-50
§ 8:7	Traditional Tobacco Litigation: Canada	8-50
§ 8:7.1	Overview	8-50
§ 8:7.2	Health Care Cost Recovery Statutes	8-50
§ 8:7.3	History of Litigation	8-52
§ 8:7.4	Recent Developments in Case Law	8-53
[A]	<i>Imperial Tobacco Canada Ltd. v. Quebec Council on Tobacco & Health</i>	8-53
[B]	Differences from the United States	8-54
§ 8:8	Vape and E-Cigarette Litigation: United States	8-54
§ 8:8.1	The FDA Deeming Regulations	8-54
§ 8:8.2	Vaping Litigation	8-57
§ 8:8.3	State Attorneys General Actions	8-59
§ 8:8.4	Vape and Respiratory Illness Litigation	8-59
§ 8:8.5	Environmental Exposure Claims Involving Vape Products and/or E-Cigarettes	8-60
§ 8:9	Vape and E-Cigarette Litigation: Canada	8-60
§ 8:9.1	Overview	8-60
§ 8:9.2	Legislative Context	8-62
§ 8:9.3	Litigation and Recent Developments in Case Law	8-64

Chapter 9 Emerging Issues in Medical Device Litigation

David R. Geiger & Peter G. Ellis

§ 9:1	Possible Exceptions to the Preemption of Claims Involving FDA Pre-Market-Approved Medical Devices	9-2
§ 9:1.1	Express and Implied Preemption Principles Generally	9-2
§ 9:1.2	Arguments for Exceptions to Preemption	9-6
[A]	Claims for Off-Label Use or Promotion	9-6
[A][1]	Express Preemption	9-7
[A][2]	Implied Preemption	9-10
[A][3]	Non-Preemption Hurdles for Off-Label Promotion Cases	9-13
[B]	Claims for Failure to Make Changes in FDA-Approved Labeling	9-15
[C]	Manufacturing Defect Claims	9-18
[D]	Express Warranty Claims	9-23

§ 9:2	Claims Arising from the Presence in the Operating Room of a Medical Device Manufacturer’s Sales Representative	9-27
§ 9:2.1	Generally	9-27
§ 9:2.2	Invasion of Privacy.....	9-28
§ 9:2.3	Battery	9-31
§ 9:2.4	Negligent Advice or Lack of Advice During Procedure.....	9-33
§ 9:2.5	Failure to Train in Use of Device	9-40
§ 9:2.6	Unauthorized Practice of Medicine	9-42
§ 9:2.7	Promotion of Off-Label Use by Not Preventing It During Procedure	9-43
§ 9:2.8	Recommended Practices for Manufacturer’s Representatives	9-45
§ 9:3	Admissibility of 510(k) Clearance Evidence.....	9-46
§ 9:3.1	Pre-Market Approval and 510(k) Clearance Generally	9-46
§ 9:3.2	Admissibility of 510(k) Clearance Evidence Under Traditional Product Liability Rules.....	9-48
§ 9:3.3	Arguments Against Admissibility of 510(k) Clearance Evidence	9-49
§ 9:3.4	Arguments in Favor of Admissibility of 510(k) Clearance Evidence	9-52

Chapter 10 Emerging Issues in Automotive Product Liability Litigation

Eric P. Conn, Howard A. Fried, Thomas N. Lurie & Nina A. Rosenbach

§ 10:1	Levels of Autonomy	10-2
§ 10:2	Safety Standards and Regulations for Fully Autonomous Vehicles	10-4
§ 10:3	Liability for Malfunctions and Breaches in Autonomous Vehicles	10-6
§ 10:3.1	Introduction.....	10-6
§ 10:3.2	Manufacturing Defects	10-8
§ 10:3.3	Design Defects.....	10-9
§ 10:3.4	Failure to Warn	10-11
§ 10:3.5	Use of Experts in Litigation	10-12
§ 10:3.6	Moral Choices in Software Development.....	10-12
§ 10:4	Cybersecurity Concerns with Autonomous Vehicles	10-13
§ 10:4.1	Data Mining and Autonomous Vehicles.....	10-13

Table of Contents

§ 10:4.2 Propriety of Autonomous Vehicle Data 10-14
§ 10:4.3 Terror Threats and Autonomous Vehicles 10-14
§ 10:5 Implications for Ridesharing and Liability Under
an Alternate Framework 10-15

Chapter 11 Emerging Issues in Food Law and Litigation

Sarah L. Brew & Joelle Groshek

§ 11:1 Overview 11-2
§ 11:2 Regulatory Framework 11-3
 § 11:2.1 Generally 11-3
 § 11:2.2 FDA 11-5
 § 11:2.3 USDA 11-9
 § 11:2.4 FTC 11-10
§ 11:3 Foodborne Illness Litigation 11-11
 § 11:3.1 Generally 11-11
 § 11:3.2 Strict Liability 11-12
 § 11:3.3 Defect 11-13
 [A] Generally 11-13
 [B] Definition of Defective Food 11-13
 [C] Proof of Defect 11-16
 § 11:3.4 Causation 11-17
 § 11:3.5 Causation in Foodborne Illness Outbreaks 11-19
 § 11:3.6 Liability Across the Supply Chain 11-20
 [A] Generally 11-20
 [B] Sellers and Distributors 11-21
 [C] “Manufacturer” of Food Products 11-21
 [D] Third-Party Auditors/Consultants 11-22
§ 11:4 Class Actions 11-23
 § 11:4.1 Foodborne Illness Outbreaks 11-23
 § 11:4.2 Consumer Fraud Litigation 11-25
 [A] Generally 11-25
 [B] Reliance 11-29
 [C] Causation 11-30
 [D] Injury 11-31
 [E] Failure to Sufficiently Plead 11-31
 [F] Preemption and Primary Jurisdiction 11-31
§ 11:5 Conclusion 11-37

Chapter 12 Regulating Cannabis Products

James H. Rotondo, Steven A. Cash & Kaitlin A. Carty

§ 12:1 Overview 12-1

§ 12:2 State and Federal Regulations 12-2

 § 12:2.1 Controlled Substances Act 12-2

 [A] Current Landscape..... 12-5

 § 12:2.2 2018 Farm Bill 12-6

 § 12:2.3 Food and Drug Administration 12-7

 [A] Approvals..... 12-7

 [B] FDA Support for Development 12-8

 [C] Enforcement and Possible Regulation 12-8

 § 12:2.4 State Legislation and Regulation 12-10

 § 12:2.5 Dual Sovereignty..... 12-14

 § 12:2.6 Preemption 12-15

 § 12:2.7 Current Case Law 12-16

 [A] Traditional Product Liability Claims 12-16

 [B] Labelling Class Actions..... 12-18

§ 12:3 Conclusion 12-19

Chapter 13 Blockchain Technology and Its Impact on Product Litigation

Justin Wales & Matt Kohen

§ 13:1 Introduction: Innovation Is Unpredictable 13-1

§ 13:2 Bitcoin, Blockchain, and Smart Contracts 13-3

 § 13:2.1 What Is Bitcoin? 13-3

 § 13:2.2 What Can a Blockchain Do? 13-4

 § 13:2.3 What Are Smart Contracts? 13-5

§ 13:3 Potential Impact on Existing Types of Products Litigation? 13-6

 § 13:3.1 Use of Blockchain in Supply Chain Records 13-6

 § 13:3.2 Admissibility and Authentication of Blockchain Evidence 13-9

 § 13:3.3 Challenges in Discovering Blockchain Data..... 13-12

§ 13:4 Who Is Liable If a Smart Contract Causes Damage?..... 13-13

 § 13:4.1 Decentralized Autonomous Organizations (DAOs)..... 13-13

 § 13:4.2 Smart Contract Developer Liability..... 13-14

§ 13:5 Conclusion 13-15

Chapter 14 Emerging Trends: Smart Technology and the Internet of Things

Christopher C. Hossellman & Damion M. Young

§ 14:1 Overview 14-2

§ 14:2 Defining the Internet of Things..... 14-3

 § 14:2.1 Generally 14-3

 § 14:2.2 Examples of IoT Products 14-4

§ 14:3 Technology and Products Liability 14-5

 § 14:3.1 Products Liability and Technology Generally..... 14-5

 § 14:3.2 Examples of Early Technology Litigation 14-6

§ 14:4 What Makes IoT Different? 14-8

 § 14:4.1 The Scale of IoT 14-8

 § 14:4.2 Web Interconnectedness and Communication..... 14-9

 § 14:4.3 Botnets and IoT 14-9

§ 14:5 Considerations in IoT Products Liability Cases 14-11

 § 14:5.1 The Hypothetical Case of the Smart Toaster..... 14-11

 § 14:5.2 Pointing to the Defect 14-12

 [A] Malfunctions 14-13

 [B] Security Breaches and Hacking 14-13

 [C] Privacy 14-14

 [D] Artificial Intelligence and Autonomous Vehicles 14-15

 § 14:5.3 IoT Discovery: Challenges of Identifying Defects in IoT Cases and the Role of Experts..... 14-17

 § 14:5.4 IoT and the Consumer Expectation Test..... 14-18

 § 14:5.5 Assigning Blame 14-20

 § 14:5.6 Challenges in Holding Software Developers Liable for Defective IoT Products 14-20

 § 14:5.7 Standing Required..... 14-21

§ 14:6 Novel Legal Theories in an IoT Ecosystem 14-21

 § 14:6.1 Curtailing the Economic Loss Doctrine 14-21

 § 14:6.2 California’s SB-327 14-23

 § 14:6.3 Federal Regulation of IoT 14-25

§ 14:7 Conclusion 14-26

Chapter 15 The Law of Damages in Product Liability Litigation

Evan D. Buxner & Dionne L. Koller

§ 15:1 Generally 15-2

 § 15:1.1 Compensatory Damages 15-2

 § 15:1.2 Recovery for Emotional Distress 15-3

 § 15:1.3 Collateral Source Rule..... 15-3

§ 15:2	Damage Caps for Non-Economic Loss.....	15-4
§ 15:3	Recovery for Pure Economic Loss	15-5
§ 15:4	Recovery of Punitive Damages.....	15-8
§ 15:4.1	Generally	15-8
§ 15:4.2	Federal Basis for Punitive Damages Award	15-9
§ 15:4.3	State Law Basis for Punitive Damages Award	15-9
§ 15:4.4	Punitive Damages Caps	15-10
§ 15:4.5	Constitutional Challenges to Punitive Damages Awards	15-10
§ 15:4.6	Ratio of Punitive Damages to Actual Damage Award	15-10
Appendix 15A	State Non-Economic Damages Caps.....	App. 15A-1
Appendix 15B	State Punitive Damages Legislation	App. 15B-1
Appendix 15C	State Punitive Damages Caps	App. 15C-1

PART II

STRATEGIES FOR MANAGING AND RESOLVING PRODUCT LITIGATION

Chapter 16 Using Early Case Assessments to Develop Strategy

Mark E. (Rick) Richardson

§ 16:1	Overview	16-2
§ 16:2	Definition of Early Case Assessment.....	16-2
§ 16:3	Uses of Early Case Assessment.....	16-3
§ 16:4	Parsing the Definition.....	16-4
§ 16:4.1	An Intentional Process.....	16-4
§ 16:4.2	With Specific Components	16-4
§ 16:4.3	Designed to Guide Strategy.....	16-5
§ 16:4.4	Done As Early As Possible	16-6
§ 16:4.5	Using Information That Will Be Incomplete but Not Inadequate.....	16-7
[A]	Focusing on Case-Determinative Information	16-7
[B]	Assessing the Importance of Unknown Information: Sensitivity Analysis.....	16-8
§ 16:5	Conducting the Early Case Assessment.....	16-9
§ 16:6	Documenting the Early Case Assessment.....	16-11
§ 16:7	Implementing the Early Case Assessment	16-12
§ 16:8	Revisiting the Strategy	16-13

Table of Contents

§ 16:9 Building Strong Counsel/Client Ties..... 16-14
§ 16:10 Conclusion 16-14
Appendix 16A Template for an Early Case
Assessment..... App. 16A-1

Chapter 17 Impact of Insurance Policies

Kamil Ismail, Linda S. Woolf & Richard M. Barnes

§ 17:1 Coverage for Defense, Indemnification and/or
Settlement of Products Liability Claims..... 17-2
§ 17:1.1 Generally 17-2
§ 17:1.2 Duty to Defend..... 17-3
 [A] Generally 17-3
 [B] Primary Policies 17-3
 [C] Excess and Umbrella Policies..... 17-6
§ 17:2 Duty to Indemnify..... 17-7
§ 17:2.1 Generally 17-7
§ 17:2.2 Insuring Provisions 17-8
 [A] CGL Policies 17-8
 [B] Claims-Made Policies 17-9
 [C] Excess and Umbrella Policies..... 17-10
 [D] Insured Contracts 17-10
§ 17:2.3 Exclusions..... 17-12
 [A] Generally 17-12
 [B] Products/Operations/Completed Operations 17-12
 [C] Known Losses 17-13
 [D] Business Risks, Recalls 17-14
 [E] Punitive Damages..... 17-15
§ 17:2.4 Conditions..... 17-16
§ 17:3 Amount of Coverage Available..... 17-19
§ 17:3.1 Policy Limits 17-19
 [A] Aggregate, Per-Occurrence and “Batch” Limits..... 17-19
 [B] Number of Occurrences 17-19
 [C] Coverage Triggers for Long-Tail Personal
 Injury Claims 17-22
 [D] “Stacking” of Policy Limits 17-24
 [E] Obligations of Multiple Insurers of the Same
 Insured in Long-Tail Personal Injury Claims..... 17-25
 [F] Exhaustion..... 17-26
 [G] Operations vs. Products Limits 17-27
§ 17:3.2 Supplementary Payments..... 17-28
§ 17:4 Emerging Issues..... 17-29
§ 17:4.1 Autonomous Vehicles 17-29
§ 17:4.2 Drones 17-29
§ 17:4.3 Cyber Risks..... 17-29

§ 17:5	Coverage Litigation.....	17-30
§ 17:5.1	Impact of Coverage Disputes on Liability Defense.....	17-30
§ 17:5.2	Ability to Resolve Coverage Dispute Before Underlying Claim.....	17-31
§ 17:5.3	Insurer’s Liability for Unreasonable Failure to Settle Claims Within Policy Limits.....	17-32
§ 17:5.4	Insured’s Right to Independent Counsel.....	17-33
§ 17:6	Conclusion.....	17-35

**Chapter 18 Advantages and Disadvantages of
Multidistrict Litigation**

Wendy R. Fleishman

§ 18:1	Overview.....	18-2
§ 18:2	Advantages of Multidistrict Litigation.....	18-2
§ 18:2.1	Efficient and Expeditious Pretrial Procedures: Avoidance of Duplication.....	18-2
§ 18:2.2	Determinations by a Single Forum.....	18-3
§ 18:2.3	A Global Point of View.....	18-5
§ 18:3	Disadvantages of the MDL Process.....	18-6
§ 18:4	Defendant’s Perspective.....	18-6
§ 18:4.1	Benefits.....	18-6
	[A] Centralized Discovery.....	18-7
	[B] Lower Transactional Costs.....	18-7
	[C] Single Dispositive Motions.....	18-8
	[D] Uniform Pleadings, Interrogatories, and Discovery Approaches.....	18-8
	[E] <i>Daubert</i> Challenges.....	18-8
§ 18:4.2	Disadvantages.....	18-9
§ 18:5	Plaintiff’s Perspective.....	18-10
§ 18:5.1	Benefits.....	18-10
§ 18:5.2	Disadvantages.....	18-12
	[A] Inconvenient Forum.....	18-12
	[B] Trial Delay.....	18-12
	[C] Concern That Plaintiff’s Individual Interests May Be Lost or Forgotten.....	18-12
	[D] Challenges to Litigants by an Unfavorable View of the Law in One Circuit Versus Another Circuit.....	18-13
	[E] Challenges to Plaintiffs’ Counsel and the Court: The Common Benefit Assessment Order and Sharing of Attorneys’ Fees.....	18-14
§ 18:6	Conclusion.....	18-18

Chapter 19 Strategies for Co-Defending Product Actions

*Lem E. Montgomery III, Anna Little Morris &
Carly Chinn*

§ 19:1	Overview	19-2
§ 19:2	Early Considerations in Multi-Defendant Actions	19-3
§ 19:2.1	Reconfiguring the Players.....	19-3
[A]	Generally	19-3
[B]	Compulsory Joinder.....	19-3
[C]	Permissive Joinder and Severance	19-5
[D]	Third-Party Practice	19-6
§ 19:2.2	Coordinating Removal Among Co-Defendants	19-8
§ 19:3	Choosing the Defense Strategy	19-12
§ 19:4	Facilitating Cooperation Among Co-Defendants	19-13
§ 19:4.1	The Joint Defense Privilege and Joint Defense Agreements.....	19-13
[A]	Generally	19-13
[B]	Ethical Considerations Surrounding Joint Defense Agreements	19-15
[C]	Drafting the Joint Defense Agreement.....	19-20
§ 19:4.2	Informal Discovery Among Co-Defendants	19-21
§ 19:5	Common Dangers of Joint Defense	19-22
§ 19:5.1	Protecting Confidential and Proprietary Information with Self-Executing and Multi-Tiered Protective Orders.....	19-22
§ 19:5.2	Ethical Considerations When Representing Multiple Defendants	19-24
§ 19:5.3	Settlement Agreements Involving Less Than All Co-Defendants; the Dangers and Risks of Mary Carter Agreements	19-27
§ 19:6	Cooperation Among Co-Defendants with Adverse Interests	19-30
§ 19:6.1	Dealing with Indemnity Obligations.....	19-30
§ 19:6.2	Sharing (or Not Sharing) Experts.....	19-31
§ 19:6.3	Mediation Strategy and Settlement Allocation Among Co-Defendants	19-33
[A]	Generally	19-33
[B]	Inform the Decision Makers.....	19-33
[C]	Evaluate the Insurance Coverage	19-34
[D]	Consider a Joint Mediation Plan.....	19-34
§ 19:6.4	Handling the Hostile Co-Defendant	19-34
§ 19:7	Checklist for Co-Defending Product Actions	19-35

Chapter 20 Crisis Management and Media Strategy

Joanne M. Gray & Nilda M. Isidro

§ 20:1	Overview	20-2
§ 20:2	The Media During a Crisis	20-3
§ 20:2.1	Role of the Media.....	20-3
§ 20:2.2	Using the Media	20-3
§ 20:2.3	Case Studies	20-4
[A]	Bridgestone/Firestone: What Not to Do When Faced with a Crisis.....	20-4
[A][1]	Background	20-4
[A][2]	Avoiding Responsibility	20-4
[A][3]	Withholding Information	20-5
[A][4]	Failure to Develop a Media Response Plan	20-6
[B]	Odwalla: Effective Crisis Management	20-7
[B][1]	Generally.....	20-8
[B][2]	Designating a Media Response Team	20-8
[B][3]	Taking Responsibility	20-9
[C]	Chipotle: Course Correcting After Years of Poor Crisis Management	20-10
[D]	Cutting Out the “Pink Slime”: How McDonald’s Used Media Outreach to Diffuse the “Yuck” Factor.....	20-12
§ 20:3	Developing an Effective Media Response Plan <i>Before a Crisis Hits</i>	20-14
§ 20:3.1	Generally	20-14
§ 20:3.2	Internal Organization—Forming a Media Response Team	20-15
§ 20:3.3	Developing Media Relationships.....	20-15
§ 20:3.4	Establishing Online Support Systems	20-16
§ 20:3.5	Conveying Company Commitment to Customers	20-17
§ 20:4	Responding to a Crisis	20-17
§ 20:4.1	Managing Media Under Fire	20-17
§ 20:4.2	Steps to Take When Responding to a Crisis	20-17
[A]	Developing a Strategic Media Message	20-17
[B]	Timely Delivery of Media Message	20-18
[C]	Opening Line of Communication	20-18
[D]	Progressive Planning.....	20-19
§ 20:5	Litigation and the Media	20-19
§ 20:5.1	Litigation Avoidance	20-19
§ 20:5.2	General Approach to Litigation.....	20-19
§ 20:5.3	Handling the Media Without Jeopardizing Lawsuits.....	20-21
[A]	Consistent Company Media Message and Strategy.....	20-21

Table of Contents

[B] Retaining Experienced Legal Counsel..... 20-21
[C] Consistent Company Media Message and Strategy..... 20-22
§ 20:6 Conclusion 20-22

VOLUME 2

Table of Chapters.....v

Chapter 21 Class Action Settlements

Richard B. Goetz, Carlos M. Lazatin & Esteban Rodriguez

§ 21:1 Overview 21-3
§ 21:2 Features of Class Action Settlements..... 21-4
 § 21:2.1 Role of the Class Representative and Class Counsel..... 21-4
 [A] Traditional Settlements..... 21-4
 [B] Class Action Settlements..... 21-4
 § 21:2.2 Judicial Approval..... 21-5
 [A] Need for Judicial Approval 21-5
 [B] Increased Judicial Scrutiny..... 21-6
 [C] Standard for Judicial Approval 21-6
 § 21:2.3 Transparency in the Settlement Process 21-8
 § 21:2.4 Multiple Parties with Goals of Derailment..... 21-9
 [A] Generally 21-9
 [B] Differences in Goals and Acceptability of Terms..... 21-10
 [C] Class Member Objections..... 21-10
§ 21:3 Basic Steps for Class Action Settlements 21-11
 § 21:3.1 Generally 21-11
 § 21:3.2 Negotiation Process 21-12
 [A] Generally 21-12
 [B] Timing of the Class Settlement 21-12
 [B][1] Generally..... 21-12
 [B][2] Pre-Suit Settlements..... 21-13
 [B][2][a] Advantages 21-13
 [B][2][b] Disadvantages 21-13
 [B][3] Early Rulings 21-14
 [B][4] Class Certification Ruling 21-14
 [B][5] Deciding Whether to Proceed to Trial..... 21-14
 [B][5][a] Generally..... 21-14

PRODUCT LIABILITY LITIGATION

[B][5][b]	Risks for Plaintiffs	21-15
[B][5][c]	Risks for Defendants	21-15
[C]	Good-Faith, Arm’s-Length Negotiations	21-16
[D]	Defining the Settlement Class	21-16
[D][1]	For Plaintiffs.....	21-17
[D][2]	For Defendants.....	21-17
[D][3]	Sub-Classes	21-18
[D][4]	Class Exclusions.....	21-18
[E]	Defining the Scope of the Release	21-19
[E][1]	What Claims Will Be Released?.....	21-19
[E][2]	What Is the Time Period Covered by the Release?.....	21-21
[E][3]	Who Will Be the “Released Parties”?.....	21-21
[F]	Consideration to Class Members.....	21-22
[F][1]	Generally.....	21-22
[F][2]	Settlement Fund Allocation.....	21-23
[F][2][a]	Claims-Made versus Lump Sum/Common Fund Settlements	21-23
[F][2][b]	Coupon Settlements.....	21-24
[F][2][c]	Voucher Settlements	21-29
[F][3]	Settlements for Sub-Classes	21-32
[F][4]	Undistributed or Unclaimed Distribution	21-33
[F][4][a]	Generally.....	21-33
[F][4][b]	<i>Cy Pres</i> Funds	21-33
[F][5]	Equitable Relief or Changes in Business Practices	21-36
[F][6]	Fairness of the Settlement Consideration.....	21-38
[G]	Incentive Award to Class Representative	21-38
[H]	Confirmatory Discovery	21-39
[I]	Notice and Administration Procedures	21-40
[I][1]	Generally.....	21-40
[I][2]	Notice’s Content and Methods of Distribution	21-40
[I][2][a]	First-Class Mail.....	21-43
[I][2][b]	Bulk Mail	21-43
[I][2][c]	Email.....	21-44
[I][2][d]	Other Methods of Notice	21-44
[I][3]	Notice’s “Reach”	21-45
[I][4]	Settlement Administration.....	21-45
[J]	Negotiating Class Counsel’s Fees	21-46
[K]	Drafting the Settlement Agreement.....	21-47
§ 21:3.3	Preliminary Approval Process	21-48
[A]	Generally	21-48
[B]	Motion for Preliminary Approval.....	21-49
[B][1]	Generally.....	21-49

Table of Contents

[B][2]	Topics Covered by the Motion.....	21-49
[B][2][a]	Summary of the History of the Litigation.....	21-49
[B][2][b]	Background of Settlement Negotiation.....	21-49
[B][2][c]	Summary Description of Settlement Terms	21-50
[B][2][d]	Provide Sound Bases for Modified Class Definition	21-51
[B][2][e]	Description of Key Factual and Legal Issues	21-51
[B][2][f]	Demonstrate Qualification for Class Certification.....	21-51
[C]	Preliminary Approval Hearing	21-54
[D]	Dealing with Potential Objectors	21-55
[D][1]	Generally.....	21-55
[D][2]	Types of Objectors	21-55
[D][3]	Defeating Objectors.....	21-56
[D][4]	Discovery of Objectors	21-57
[D][5]	Settling with Objectors.....	21-59
[E]	Requests to Enjoin Competing Class Actions	21-60
§ 21:3.4	Fairness Hearing Process.....	21-61
[A]	Generally	21-61
[B]	Setting the Timetable for the Fairness Hearing.....	21-61
[C]	CAFA's Notice Requirements for Government Officials	21-62
[D]	Submissions for the Fairness Hearing.....	21-64
[E]	Use of Experts and Other Witnesses for the Fairness Hearing.....	21-65
[F]	Conduct of the Fairness Hearing	21-66
§ 21:4	Risks of a Failed Class Settlement	21-67
§ 21:4.1	Changes to the Players and Dynamics	21-67
§ 21:4.2	Defendant's Diminished Leverage	21-68
§ 21:4.3	Bar to Challenging Class Certification.....	21-68
§ 21:4.4	Financial Impact on the Defendant.....	21-70
§ 21:5	State Intervention in Class Action Settlements	21-70

Chapter 22 Mass Tort Settlement Strategies

Richard B. Goetz & Carlos M. Lazatin

§ 22:1	Overview	22-2
§ 22:2	Settlement Strategies	22-3
§ 22:2.1	Settlement Class Actions.....	22-3
[A]	Generally	22-3
[B]	Heightened Scrutiny of Certification Requirements.....	22-5
[C]	Opt-Out Rights.....	22-6
[D]	Appellate Review Concerns.....	22-8

PRODUCT LIABILITY LITIGATION

§ 22:2.2 Inventory Settlements..... 22-8
 [A] Generally 22-8
 [B] Benefits..... 22-9
 [C] Drawbacks..... 22-9
§ 22:2.3 Settlement Funds 22-11
§ 22:2.4 Hybrid Approach..... 22-13
§ 22:2.5 Aggregate Settlement Agreements with
 Plaintiffs' Attorneys 22-14
 [A] Generally 22-14
 [B] *Propulsid*® Litigation..... 22-16
 [B][1] Background 22-16
 [B][2] First Settlement Agreement..... 22-16
 [B][3] Second Settlement Agreement..... 22-18
§ 22:3 Private Settlement Agreement: *Vioxx* Settlement 22-19
 § 22:3.1 Background 22-19
 § 22:3.2 Pre-Settlement Proceedings..... 22-19
 § 22:3.3 Settlement Agreement 22-21
 § 22:3.4 Subsequent Developments and Issues..... 22-27
§ 22:4 Additional Mass Tort Settlement Structure..... 22-30
§ 22:5 The Negotiation Class..... 22-34
§ 22:6 Additional Issues for Consideration..... 22-36

Chapter 23 Arbitration

Beth L. Kaufman & Charles B. Updike

§ 23:1 Overview 23-1
§ 23:2 Agreement to Arbitrate 23-2
 § 23:2.1 Generally 23-2
 § 23:2.2 Benefits..... 23-3
 § 23:2.3 Pitfalls..... 23-3
 [A] Broad Language..... 23-3
 [B] Multiple Outcomes..... 23-4
 [C] Finality 23-5
§ 23:3 Post-Claim Agreements to Arbitrate..... 23-5
§ 23:4 Individual Claims by End-Users 23-6
 § 23:4.1 Generally 23-6
 § 23:4.2 Arbitration Considerations 23-6
 § 23:4.3 Voluntary Arbitration Rules 23-7
§ 23:5 Arbitration in “Mass Tort” Product Liability
 Claims..... 23-8
 § 23:5.1 Background..... 23-8
 § 23:5.2 Benefits..... 23-9
§ 23:6 Conclusion 23-10

Chapter 24 Privilege in a Global Product Economy

Marina G. McGuire & Josephine A. Reina

§ 24:1	Overview	24-2
§ 24:2	Attorney-Client Privilege	24-3
§ 24:2.1	Generally	24-3
§ 24:2.2	Who Is the Client?	24-5
§ 24:2.3	What Communications Are Protected by the Attorney-Client Privilege?	24-7
§ 24:2.4	Whose Law Applies?	24-8
§ 24:3	Question of Voluntary Waiver	24-10
§ 24:3.1	Voluntary Waiver During Government Investigations	24-10
[A]	“Holder” Memo	24-10
[B]	“Thompson” Memo	24-11
[C]	“McCallum” and “McNulty” Memos	24-11
[D]	Senator Arlen Specter and Deputy Attorney General Mark R. Filip	24-13
[E]	“Yates” Memo	24-15
§ 24:3.2	Voluntary Waiver During SEC Investigations	24-16
[A]	The Seaboard Report	24-16
[B]	The SEC’s Enforcement Manual and Enforcement Initiative	24-17
§ 24:3.3	Selective Waiver	24-19
§ 24:4	Questions of Involuntary Waiver by In-House Counsel During EU Investigations	24-20
§ 24:4.1	Generally	24-20
§ 24:4.2	The “Attorney” and Privilege in the EU	24-21
§ 24:5	Attorney-Client Privilege Issues Today	24-25
§ 24:5.1	The Implications of Voluntary Waiver	24-25
§ 24:5.2	The Implications of Involuntary Waiver Post- <i>Akzo Nobel</i>	24-26
§ 24:5.3	The Implications of Communications with Counsel That Involve a “Dual Purpose”	24-27
§ 24:6	Conclusion	24-27

Chapter 25 E-Discovery—Practical Considerations

*Denise J. Talbert, John C. Vaglio, Jeremiah S. Wikler &
Christy A. Pulis*

§ 25:1	Overview	25-2
§ 25:2	Guiding Principles	25-3
§ 25:2.1	Generally	25-3
§ 25:2.2	Be Transparent	25-4

PRODUCT LIABILITY LITIGATION

§ 25:2.3	Be Technologically Competent	25-7
§ 25:2.4	Use Discovery Responses to Define Production Scope	25-7
§ 25:2.5	Avoid Discovery on Discovery	25-8
§ 25:2.6	Comply with the Amended Federal Rules of Civil Procedure	25-9
§ 25:2.7	Allow for Litigation-Specific Circumstances	25-11
§ 25:3	Developing and Implementing the E-Discovery Plan	25-13
§ 25:3.1	Preservation	25-13
[A]	Generally	25-13
[B]	Hold Notice Language and Distribution	25-14
[C]	Continuing Obligation	25-16
[D]	ESI Preservation Considerations	25-16
[E]	Separating Employees	25-17
[F]	Tips to Reduce Preservation Costs	25-18
§ 25:3.2	Collection	25-18
[A]	Generally	25-18
[B]	Collection Plan	25-19
[B][1]	Scope Statement	25-19
[B][2]	Whom to Collect From	25-20
[B][3]	Collection Interview	25-20
[C]	Execution of a Document Collection	25-22
[C][1]	Hard Copy Collection	25-22
[C][2]	Electronic Collection	25-23
[D]	Tips to Reduce Collection Costs	25-25
§ 25:3.3	Processing	25-26
[A]	Vendors	25-26
[B]	Vendor Selection	25-27
[C]	Processing Issues	25-28
[C][1]	De-duplication	25-28
[C][2]	Email Threading	25-29
[C][3]	Filters	25-30
[C][4]	Review Enhancers	25-30
[D]	Tips to Reduce Processing Costs	25-31
§ 25:3.4	Review	25-31
[A]	Review Guidelines	25-31
[A][1]	Responsiveness	25-32
[A][2]	Confidentiality	25-32
[A][3]	Privilege	25-32
[B]	Review Team	25-33
[C]	Technology-Assisted Review	25-34
[D]	Tips to Reduce Review Costs	25-35

Table of Contents

§ 25:3.5	Production	25-36
[A]	Protective Orders	25-36
[B]	ESI Protocols.....	25-37
[B][1]	Offensive Uses of ESI Protocol	25-37
[C]	Preparation of Productions.....	25-38
[D]	Tracking Productions	25-38
[E]	Tips to Reduce Production Costs	25-39
§ 25:4	Conclusion	25-39

Chapter 26 Expert Evidence—Law, Strategies and Best Practices

*Stephanie A. Scharf, George D. Sax,
Sarah R. Marmor & Abir Ahmed*

§ 26:1	Overview	26-2
§ 26:2	Standards for Admissibility of Expert Opinions in Federal Court: <i>Frye</i> , <i>Daubert</i> , and Rule 702.....	26-4
§ 26:2.1	The Frye Standard.....	26-4
§ 26:2.2	The Road to Daubert	26-5
§ 26:2.3	Daubert and Its Aftermath.....	26-7
§ 26:2.4	Federal Rule of Evidence 702.....	26-9
§ 26:2.5	Trial Court As Evidentiary Gatekeeper.....	26-10
§ 26:2.6	Other Evidentiary Rules.....	26-12
§ 26:3	Current Issues Around Rule 702	26-13
§ 26:3.1	Is It Time to Amend Rule 702?.....	26-13
§ 26:3.2	Application of Rule 702	26-17
§ 26:3.3	Ongoing Differences Between Daubert and Frye.....	26-20
§ 26:4	Exemplar States	26-21
§ 26:4.1	California.....	26-21
§ 26:4.2	Florida	26-24
§ 26:4.3	Illinois	26-25
§ 26:4.4	New Jersey.....	26-27
§ 26:4.5	New York.....	26-29
§ 26:4.6	Ohio	26-30
§ 26:4.7	Pennsylvania.....	26-31
§ 26:4.8	Texas.....	26-33
§ 26:5	<i>Daubert/Frye</i> in Practice	26-35
§ 26:5.1	Establishing Causation Through Expert Testimony.....	26-35
§ 26:5.2	Preparing for Daubert/Frye Challenges.....	26-37
§ 26:6	Federal Rule of Civil Procedure 26	26-40
§ 26:7	Conclusion	26-41
Appendix 26A	State Standards for Admissibility of Expert Evidence (As of April 2023).....	App. 26A-1

Chapter 27 Court-Appointed and Unconventional Expert Issues

Jonathan M. Hoffman

§ 27:1 Overview 27-2

 § 27:1.1 Reasons for Court-Appointed Experts 27-4

§ 27:2 Court-Appointed Experts Under Rule 706 27-6

 § 27:2.1 Generally 27-6

 § 27:2.2 Interpretation of Rule 706’s Provisions 27-8

 [A] Trial Court’s Discretion Whether to Appoint Experts 27-8

 [B] Procedure for Invoking Rule 706 27-10

 § 27:2.3 Strategy 27-10

 [A] Whether the Court Should Appoint Its Own Experts 27-10

 [A][1] Benefits of Court-Appointed Experts 27-11

 [A][2] Risks of Using Court-Appointed Experts 27-12

 [B] Selecting a Court-Appointed Expert Witness 27-13

 [C] Scope of Testimony 27-15

 § 27:2.4 Instructions to Appointed Witnesses 27-16

 [A] Text of Rule 706 27-16

 [B] Strategy 27-16

 [B][1] Court’s Instructions to Appointed Witnesses 27-16

 [B][2] Research Methods of Court-Appointed Experts 27-17

 [B][3] Communications with Others 27-17

 [B][4] Ex Parte Communications with Parties or Their Experts 27-17

 [B][5] Ex Parte Communications with the Court 27-18

 [B][6] Acquisition of Information 27-18

 [B][7] Reports 27-19

 [B][8] Document Retention 27-20

 [B][9] Depositions 27-20

 [B][10] Motions in Limine 27-21

 [B][11] Disclosure of Experts’ Status 27-21

 [C] Payment of Experts’ Costs 27-21

§ 27:3 Technical Advisors 27-22

 § 27:3.1 Generally 27-22

 § 27:3.2 Court’s Inherent Authority 27-23

 § 27:3.3 Procedural Protections 27-25

 § 27:3.4 Costs 27-27

§ 27:4 Our Future? Getting into the Hot Tub 27-27

 § 27:4.1 Origins of Hot Tubbing 27-28

 § 27:4.2 Hot Tubbing in the United States 27-29

Chapter 28 Statistical Evidence in Products Liability Litigation

Nathan A. Schachtman

§ 28:1	History and Overview.....	28-2
§ 28:2	Litigation Context of Statistical Issues	28-3
§ 28:3	Qualifications of Expert Witnesses Who Give Testimony on Statistical Issues.....	28-4
§ 28:4	Admissibility of Statistical Evidence— Rules 702 and 703.....	28-5
§ 28:5	Significance Probability.....	28-6
§ 28:5.1	Definition of Significance Probability (The “p-value”)	28-6
§ 28:5.2	Misstatements about Statistical Significance	28-7
§ 28:5.3	Transposition Fallacy	28-12
§ 28:5.4	Confusion Between Significance Probability and Burden of Proof	28-13
§ 28:5.5	Hypothesis Testing.....	28-15
§ 28:5.6	Confidence Intervals.....	28-15
§ 28:5.7	Inappropriate Use of Statistics— <i>Matrixx Initiatives</i>	28-17
[A]	Sequelae of <i>Matrixx Initiatives</i>	28-20
[B]	Is Statistical Significance Necessary?	28-23
§ 28:5.8	American Statistical Association’s Statement on P-Values.....	28-26
§ 28:6	Statistical Power	28-29
§ 28:6.1	Definition of Statistical Power	28-29
§ 28:6.2	Cases Involving Statistical Power.....	28-31
§ 28:7	Evidentiary Rule of Completeness	28-35
§ 28:8	Meta-Analysis.....	28-36
§ 28:8.1	Definition and History of Meta-Analysis	28-36
§ 28:8.2	Consensus Statements.....	28-37
§ 28:8.3	Use of Meta-Analysis in Litigation.....	28-37
§ 28:8.4	Competing Models for Meta-Analysis.....	28-41
§ 28:8.5	Recent Cases Involving Meta-Analyses	28-42
§ 28:9	Statistical Inference in Securities Fraud Cases Against Pharmaceutical Manufacturers	28-47
§ 28:10	Multiple Testing	28-53
§ 28:11	Ethical Considerations Raised by Statistical Expert Witness Testimony	28-55
§ 28:12	Conclusion	28-55

PART III
PARTICULAR ISSUES AND TACTICS

Chapter 29 Post-Sale Responsibilities in the United States and Foreign Countries

Kenneth Ross & George W. Soule

§ 29:1	Overview	29-2
§ 29:2	U.S. Common Law	29-3
§ 29:2.1	Generally	29-3
§ 29:2.2	Third Restatement Law on Post-Sale Duty to Warn	29-3
[A]	Section 10	29-3
[B]	Section 11	29-4
[C]	Section 13	29-4
§ 29:2.3	State Courts	29-5
[A]	Third Restatement	29-5
[B]	Subsequent Safety Improvements	29-5
§ 29:3	U.S. Regulatory Law	29-7
§ 29:3.1	Generally	29-7
§ 29:3.2	Consumer Product Safety Act	29-7
§ 29:4	Foreign Regulatory Activity	29-8
§ 29:4.1	Generally	29-8
§ 29:4.2	European Response	29-8
§ 29:4.3	Foreign Standards and Regulations	29-9
§ 29:5	Meeting a Manufacturer's Post-Sale Duties	29-10
§ 29:5.1	Information-Gathering Network	29-10
§ 29:5.2	Risk Assessment	29-11
§ 29:5.3	Determining the Necessity of Post-Sale Action	29-12
§ 29:6	Defending a Product After a Recall	29-13
§ 29:6.1	Generally	29-13
§ 29:6.2	Manufacturer Strategies	29-13
[A]	Act Decisively and Expeditiously in Conducting the Recall	29-13
[B]	Draft the Recall Message with Care	29-14
[C]	Identify "Losers" and "Winners"	29-14
[D]	Weigh Pros and Cons of Excluding Recall Evidence	29-14
[E]	Prepare Arguments for Excluding Recall Evidence	29-15
[F]	Police Claims Against Manufacturer	29-16
[G]	Put the Risk of Injury into Perspective	29-17
[H]	Tell the Due Care Story	29-17

Table of Contents

[I]	Prove Accident Not Due to Recall Condition.....	29-17
[J]	Prove Another Factor Caused the Accident.....	29-18
[K]	Try the Comparative Fault Case Against Others.....	29-18
§ 29:7	Conclusion	29-18

Chapter 30 Role of Corporate Executives

Samuel Goldblatt & Benjamin R. Dwyer

§ 30:1	Overview	30-1
§ 30:2	Limitations on Depositions of High-Level Executives.....	30-2
§ 30:2.1	Generally	30-2
§ 30:2.2	Law of “Apex” Depositions.....	30-4
§ 30:2.3	Unique or Superior Knowledge.....	30-7
§ 30:2.4	Less Burdensome Means.....	30-12
§ 30:3	Plaintiff’s Strategic Considerations.....	30-18
§ 30:4	Defense’s Strategic Considerations	30-20
§ 30:5	Negotiating the Scope of Depositions	30-22
§ 30:6	Preparation of a High-Level Executive for Deposition and Trial.....	30-22
§ 30:7	Conclusion	30-23

Chapter 31 Contacting Corporate Employees

*Sharon L. Caffrey, Kenneth M. Argentieri &
Rachel M. Good*

§ 31:1	Overview	31-1
§ 31:2	Initiating an Ex Parte Communication	31-2
§ 31:2.1	Initial Considerations	31-2
§ 31:2.2	Applicable Rules.....	31-2
§ 31:3	Who Is a Represented Party?	31-5
§ 31:3.1	Model Rule 4.2	31-5
§ 31:3.2	Court Opinions.....	31-6
§ 31:3.3	American Bar Association.....	31-9
§ 31:4	Claiming an Attorney-Client Relationship	31-10
§ 31:4.1	Attorney-Client Privilege.....	31-10
§ 31:4.2	Protecting Confidential Information	31-11
§ 31:5	Conclusion	31-13

Chapter 32 Spoliation of Product Evidence

Paul E. Benson & Adam E. Witkov

§ 32:1	Overview	32-2
§ 32:2	History of Spoliation of Evidence.....	32-3
§ 32:3	Analysis of Recent Trends in Spoliation.....	32-4
§ 32:3.1	Generally	32-4
§ 32:3.2	Reasonably Foreseeable Litigation and Document Retention Policies.....	32-4
§ 32:3.3	Spoliation of Electronically Stored Information.....	32-5
§ 32:3.4	State Court Trends.....	32-6
§ 32:4	Negligent Spoliation	32-7
§ 32:4.1	Generally	32-7
§ 32:4.2	Negligent Spoliation by a Plaintiff.....	32-8
§ 32:4.3	Negligent Spoliation by a Defendant.....	32-9
§ 32:4.4	Negligent Spoliation by a Third Party	32-11
[A]	Generally	32-11
[B]	Duty to Preserve Evidence	32-12
§ 32:5	Intentional Spoliation.....	32-14
§ 32:5.1	Generally	32-14
§ 32:5.2	Intentional Spoliation by a Plaintiff	32-14
§ 32:5.3	Intentional Spoliation by a Defendant	32-15
§ 32:5.4	Intentional Spoliation by a Third Party.....	32-18
[A]	Generally	32-18
[B]	Third-Party Intentional Spoliation Not Protected.....	32-20
§ 32:6	Defenses and Sanctions	32-21
§ 32:6.1	Defenses	32-21
[A]	Good Faith.....	32-21
[B]	Opportunity to Examine	32-22
[C]	Immaterial Evidence	32-23
[D]	Statutes of Limitations	32-23
§ 32:6.2	Sanctions	32-24
[A]	Generally	32-24
[B]	Dismissal.....	32-25
[C]	Monetary Sanctions.....	32-26
[D]	Spoliation Inference/Rebuttable Presumption	32-27
[E]	Criminal Liability for Obstruction of Justice.....	32-29
§ 32:7	Evolving Areas	32-30
§ 32:7.1	Party Sophistication	32-30
§ 32:7.2	Video Evidence.....	32-30
§ 32:7.3	Freedom of Information Act (FOIA).....	32-31
§ 32:8	Attorney Duties	32-31
§ 32:9	Conclusion	32-32

Chapter 33 Presenting Complex Scientific Evidence

Morton D. Dubin II & Nina Trovato

§ 33:1	Overview	33-2
§ 33:2	Selecting a Message	33-2
§ 33:2.1	Generally	33-2
§ 33:2.2	Understand the Scientific Evidence.....	33-3
§ 33:2.3	Simplify the Trial Message.....	33-3
§ 33:2.4	Expert Credibility Themes	33-4
§ 33:3	Selecting a Messenger—Importance of the Right Expert.....	33-6
§ 33:4	Considerations During Phases of the Trial Process	33-7
§ 33:4.1	Jury Selection.....	33-7
§ 33:4.2	Opening.....	33-7
§ 33:4.3	Direct Examination	33-8
[A]	State Opinions at the Outset	33-8
[B]	Tactical Presentation of Qualifications.....	33-9
[C]	Use of Visual Aids	33-10
[D]	Get Experts on Their Feet.....	33-10
[E]	Develop Themes.....	33-10
[F]	Draw Implied Conclusions	33-11
[G]	Understand Local Rules on Learned Treatises	33-11
[H]	“Gateway” Requirements.....	33-13
§ 33:4.4	Cross-Examination	33-14
[A]	Understand Local Rules on Learned Treatises.....	33-14
[B]	Know Your Limitations and the Skill of the Expert	33-16
[C]	Focus on the Understandable.....	33-16
[D]	Best Available Tools for Organization and Presentation.....	33-17
[E]	Strategic Use of Bias Information	33-17
§ 33:4.5	Closing	33-17

Chapter 34 How to Win a Dismissal When the Plaintiff Declares Bankruptcy

Anita Hotchkiss & Earyn Edwards

§ 34:1	Overview	34-2
§ 34:2	Types of Bankruptcies	34-3
§ 34:2.1	Chapter 7.....	34-4
§ 34:2.2	Chapter 13.....	34-4
§ 34:3	Duty to Disclose Pending and Contingent Claims.....	34-5
§ 34:3.1	Generally	34-5
§ 34:3.2	Definition of “Pending Claims”	34-5

PRODUCT LIABILITY LITIGATION

§ 34:4 Standing 34-6

 § 34:4.1 Generally 34-6

 § 34:4.2 Standing and Bankruptcy 34-6

§ 34:5 Judicial Estoppel 34-8

 § 34:5.1 Generally 34-8

 § 34:5.2 Judicial Estoppel and Bankruptcy 34-9

 § 34:5.3 Elements Needed to Prove Entitlement to
 Summary Judgment 34-11

 [A] Generally 34-11

 [B] Knowledge 34-12

 [C] Bad Faith 34-13

 [D] Detrimental Reliance 34-15

 [E] Public Policy 34-15

 § 34:5.4 Choice of Law 34-15

 [A] Generally 34-15

 [B] Property Exemptions Specific to Particular
 Jurisdictions 34-16

 [C] Significance of the Amount of Debt
 Discharged 34-17

§ 34:6 Securing Dismissal or Summary Judgment 34-17

§ 34:7 Plaintiff’s Responses to an Estoppel Motion 34-19

 § 34:7.1 Generally 34-19

 § 34:7.2 Amending the Bankruptcy Petition 34-20

 § 34:7.3 Allowing the Bankruptcy Trustee to
 Prosecute the Case 34-21

 § 34:7.4 Suing the Bankruptcy Attorney for
 Malpractice 34-22

§ 34:8 Conclusion 34-22

Appendix 34A Cases Seeking Summary Judgment/Dismissal
 Based Upon Judicial Estoppel and/or
 Lack of Standing App. 34A-1

Chapter 35 Juries

Christopher C. Spencer

§ 35:1 Introduction 35-2

§ 35:2 Why Go to Trial? 35-3

§ 35:3 The Modern Jury Trial 35-4

§ 35:4 The Modern Jury 35-4

§ 35:5 Preparing for Your Performance 35-7

 § 35:5.1 First Steps 35-8

 § 35:5.2 Take Control of the Narrative 35-9

 § 35:5.3 Experts 35-10

 § 35:5.4 Taking Depositions 35-11

Table of Contents

§ 35:5.5	Defending Depositions	35-12
§ 35:5.6	Jury Research	35-14
§ 35:6	Staging.....	35-14
§ 35:6.1	Jury Instructions and Verdict Form	35-15
§ 35:6.2	Pretrial Motions.....	35-16
§ 35:6.3	Exhibits.....	35-16
§ 35:6.4	Witnesses.....	35-19
§ 35:6.5	Get Acquainted with the Courtroom	35-20
§ 35:7	Showtime	35-21
§ 35:7.1	First Impressions	35-21
§ 35:7.2	Look Your Part	35-22
§ 35:7.3	Have Your Witnesses and Representatives Look Their Parts	35-22
§ 35:7.4	First Impressions, Continued.....	35-23
§ 35:7.5	Picking the Jury	35-24
§ 35:7.6	Opening.....	35-24
§ 35:7.7	The Evidence	35-25
§ 35:7.8	The Defense and Damages	35-25
§ 35:7.9	The Plaintiff and Anger	35-26
§ 35:7.10	Lead the Jury, Don't Push It.....	35-26
§ 35:7.11	Closing	35-26
§ 35:8	Conclusion	35-26

Chapter 36 Preparing for the Appeal

Wendy F. Lumish & Alina Alonso Rodriguez

§ 36:1	Overview	36-2
§ 36:2	Pre-Trial.....	36-2
§ 36:2.1	Drafting Pleadings and Dispositive Motions.....	36-2
§ 36:2.2	Motions in Limine.....	36-3
§ 36:2.3	Experts.....	36-5
§ 36:2.4	Pre-Trial Stipulation.....	36-6
§ 36:3	Trial.....	36-7
§ 36:3.1	The Record	36-7
[A]	Generally	36-7
[B]	Depositions	36-8
[C]	Exhibits	36-8
[D]	Non-Verbal Conduct	36-9
[E]	Filing Documents During Trial.....	36-10
§ 36:3.2	Voir Dire.....	36-10
§ 36:3.3	Evidentiary Objections.....	36-12
§ 36:3.4	Expert Testimony Revisited.....	36-15
§ 36:3.5	Proffers of Evidence.....	36-16
§ 36:3.6	Motion for Directed Verdict	36-16
§ 36:3.7	Jury Instructions.....	36-17

§ 36:3.8	Verdict Form	36-22
§ 36:3.9	Closing Argument.....	36-24
§ 36:3.10	Juror Misconduct	36-24
§ 36:4	Post-Trial	36-25

Chapter 37 Global Reach: Foreign Defendants in the United States

Lisa J. Savitt

§ 37:1	Introduction	37-2
§ 37:2	Initial Considerations.....	37-3
§ 37:2.1	Service of Process.....	37-3
§ 37:2.2	Internationally Agreed Means of Service.....	37-4
§ 37:2.3	Waiver.....	37-5
§ 37:2.4	Service of Process Under the Foreign Sovereign Immunities Act (FSIA).....	37-5
§ 37:2.5	Removal.....	37-7
§ 37:2.6	Duty to Preserve and Litigation Hold.....	37-7
§ 37:2.7	Personal Jurisdiction	37-7
[A]	Specific Jurisdiction	37-8
[A][1]	Post <i>Bristol-Myers</i> Decisions	37-11
[B]	General Jurisdiction.....	37-12
[B][1]	Legal Challenges to <i>Daimler</i> and Progeny.....	37-13
[C]	Practical Considerations	37-13
§ 37:2.8	Subject Matter Jurisdiction	37-13
§ 37:2.9	The Foreign Sovereign Immunities Act (FSIA).....	37-14
§ 37:2.10	<i>Forum Non Conveniens</i>	37-14
§ 37:3	Considerations During Litigation	37-15
§ 37:3.1	Discovery Issues	37-15
§ 37:3.2	Hague Convention on Taking of Evidence Abroad	37-16
§ 37:3.3	Foreign Privacy Issues	37-17
§ 37:3.4	Attorney-Client Privilege.....	37-17
§ 37:3.5	Application of Foreign Law	37-18
§ 37:4	Other Differences	37-19
§ 37:5	Enforcement of Judgments.....	37-19
§ 37:6	Cultural Issues	37-20
§ 37:7	Conclusion	37-20

Table of Cases	T-1
-----------------------------	-----

Index	I-1
--------------------	-----